Thrombosis in coronary artery disease: Its pathophysiology and control

Dialogues in Cardiovascular Medicine

Volumn 7, Issue 1, 2002, Pages 3-18

  Theroux, Pierre ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

Author keywords

Acute coronary syndrome; Anticoagulant; Antiplatelet; Coagulation; Coronary thrombosis; Platelet; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ADENOSINE RECEPTOR BLOCKING AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CELECOXIB; CILOSTAZOL; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; DAZOXIBEN; DIPYRIDAMOLE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; INDOBUFEN; KETANSERIN; LOW MOLECULAR WEIGHT HEPARIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PURINERGIC RECEPTOR BLOCKING AGENT; PYRIDINE DERIVATIVE; RIDOGREL; ROFECOXIB; SULFINPYRAZONE; THROMBIN INHIBITOR; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; THROMBOXANE SYNTHASE INHIBITOR; TICLOPIDINE; TRIFLUSAL; UNINDEXED DRUG;

ACUTE DISEASE; ANTICOAGULANT THERAPY; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; BLOOD CLOTTING; BLOOD VESSEL WALL; CLINICAL TRIAL; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; CORONARY STENT; DISEASE CONTROL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG TRANSFORMATION; DRUG USE; GASTROINTESTINAL HEMORRHAGE; GENITAL BLEEDING; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATION; MEDICAL DECISION MAKING; MOLECULAR BIOLOGY; NEUTROPENIA; PATHOPHYSIOLOGY; RETROPERITONEAL HEMORRHAGE; REVIEW; ST SEGMENT ELEVATION; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA; THROMBOGENESIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; URINARY TRACT HEMORRHAGE;

EID: 0037591149     PISSN: 12729949     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Davies MJ. The birth, growth, and consequences of the atherosclerotic plaque. Dialogues Cardiovasc Med. 1999;4:115-178.
2. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 1995;91:2844-2850.
3. Goldstein JA, Demetriou D, Grines CL, et al. Multiple complex coronary plaques in patients with acute myocardial infarction. N Engl J Med. 2000;343:915-922.
4. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
5. Ridker PM, Rifai N, Clearfield M, et al. The Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin, therapy in the primary prevention, of acute coronary, events. N Engl J Med. 2001;344:1959-1965.
6. Hamm CW, Heeschen C, Goldmann B, et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. N Engl J Med. 1999;340:1623-1629.
7. Lindahl B, Venge P, Wallentin L. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group. J Am Coll Cardiol. 1997;29:43-48.
8. Daniel JL, Dangelmaier C, Jin J, Ashby B, Smith JB, Kunapuli SP. Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets. J Biol Chem. 1998;273:2024-2029.
9. 3) inhibitors. Blood. 1998;92:3240-3249.
10. Collaborative overview of randomised trials of antiplatelet therapy-I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ. 1994;308:81-106.
11. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143:1-13.
12. European Study of Prevention of Infarct with Molsidomine (ESPRIM) Group. The ESPRIM trial: short-term treatment of acute myocardial infarction with molsidomine. Lancet. 1994, 344:91-97.
13. Patrono C, Coller B, Dalen JE, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest. 1998;114(suppl):470S-488S.
14. Hebert PR, Hennekens CH. An overview of the 4 randomized trials of aspirin therapy in the primary prevention of vascular disease. Arch Intern Med. 2000;160:3123-3127.
15. 2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT). Circulation. 1994;89:588-595.
16. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cycloaxygenase-2. N Engl J Med. 2001;345:433-442.
17. Gent M, Beaumont D, Blanchard J, et al. The CAPRIE Steering Committee. A randomised, blinded, trial of Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348:1329-1339.
18. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
19. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
20. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancer. 1997;349:1429-1435.
21. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998;352:87-92.
22. The ESPRIT investigators. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial. JAMA. 2001;285:2468-2473.
23. Topol EJ, Moliterno DJ, Herrmann HC, et al. The TARGET Investigators. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001;344:1888-1894.
24. The GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early revascularisation: the GUSTO IV-ACS randomised trial. Lancet. 2001;357:1915-1924.
25. The PRISM-PLUS Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms. N Engl J Med. 1998;338:1488-1497.
26. The PURSUIT Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med. 1998;339:436-443.
27. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. The TACTICS - Thrombolysis in Myocardial Infarction 18 Investigators. N Engl J Med. 2001;344:1879-1887.
28. The GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet. 2001;357:1905-1914.
29. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet. 2001;358:605-613.
30. Montalescot G, Barragan P, Wittenberg O, et al. The ADMIRAL Investigators. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344:1895-1903.
31. Chew DP, Bhatt DL, Sapp S, Topol EJ. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists. A meta-analysis of phase III multicenter randomized trials. Circulation. 2001;103:201-206.
32. Hirsh J, Weitz JI. Thrombosis and anticoagulation. Semin Hematol. 1999;36:118-132.
33. Herbert JM, Petitou M, Lormeau JC, et al. SR 90107A/Org 31540, a novel anti-factor Xa antithrombotic agent. Cardiovasc Drug Rev. 1997;15:1-26.
34. Turpie AGG, Gallus AS, Hoek JA. The Pentasaccharide Investigators. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med. 2001;344:619-625.
35. Eikelboom JW, Anand SS, Malmberg K, et al. Urfactionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet. 2000;355:1936-1942.
36. Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med. 1992;327:141-145.
37. The FRISC Study Group. Low-molecular-weight heparin during instability in coronary, artery disease. Lancet. 1996;347:561-568.
38. Cohen M, Demers C, Gurfinkel EP, et al. The Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary disease. N Engl J Med. 1997,337:447-452.
39. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) IIB trial. Circulation. 1999;100:1593-1601.
40. Klein W, Buchwald A, Hillis SE, et al. For the FRIC Investigators. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Circulation. 1997;96:61-68.
41. The FRAXIS Study group. Comparison of two treatment durations (6 days and 14 days) of a low-molecular-weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q-wave myocardial infarction. Eur Heart J. 1999;20:1553-1562.
42. Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation. 1999;100:1602-1608.
43. FRagmin and Fast Revascularisation during InStability in Coronary artery disease (FRISC II) investigators. Low-molecular-mass heparin in unstable coronary artery disease: FRISC II prospective randomised multicentre study. Lancet. 1999;354:701-707.
44. Verheugt FWA, Brouwer MA, Van RFE, Ezekowitz MD, Fiore L, Fuster V. Risks versus benefit of oral anticoagulation on top of aspirin following unstable angina or myocardial infarction: a meta-analysis. Circulation. 2001;104(suppl II):17:II88-424.
45. The Global Use of Strategies to Open occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med. 1996;335:775-782,
46. The OASIS-2 Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularization procedures in patients with acute myocardial ischaemia without ST elevation: a randomized trial. Organization to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Lancet. 1999;353:429-438.
47. ThRombin Inhibition In Myocardial ischaemia (TRIM) Study Group. A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary disease in 1209 patients. Eur Heart J. 1997;18:1415-1425.
48. Bittl JA, Strony J, Brinker JA, et al. The Hirulog Angioplasty Study Investigators. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med. 1995;333:764-769.
49. White HD and the HERO-2 Investigators. The Hirulog and Early Reperfusion/Occlusion (HERO-2) trial. Results presented at the European Society of Cardiology Scientific Sessions, Stockholm, Sweden, August 2001.